[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"guideline-adherence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:guideline-adherence":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100645568","guideline-implementation-and-quality-of-care-evaluation-in-patients-with-heart-failure-and-reduced-ejection-fraction-hfref-100645568",false,"NCT07702760","Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)","Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF): The IMPLEMENT-HF Study.","IMPLEMENT HF","Inclusion Criteria:\n\n1. Written informed consent\n2. Age ≥18 years\n3. Diagnosis of HFrEF according to ESC HF guidelines (EF \\\u003C40%)\n4. Participant is willing to participate for 1 years of follow-up for standard of care at the outpatient clinic of the participating hospital and the local investigator follows the patients for the time frame of 1 years on reported endpoints.\n\nExclusion Criteria:\n\n1. An expected life expectancy less than 1 year due to other comorbidities according to the treating physician\n2. A major CV event (e.g. disabling stroke, myocardial infarction, open heart surgery) within 3 months of enrollment, if likely to interfere with GDMT titration or regular follow-up.\n3. Advanced or Endstage Heart Failure stage in which advanced HF treatment with an LVAD or heart transplant is anticipated within 6 months after the baseline visit.\n\nAt enrollment the patient has heart failure with reduction ejection fraction with an established EF below 40%.","ALL","18 Years",{"count":20,"type":21},1500,"ESTIMATED","12 Months","OBSERVATIONAL","The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4 pillars of guideline directed medical therapy (GDMT) in HFrEF patients will help to further improve the implementation of GDMT.\n\nData will be used from the national HF registry in the Netherlands. Two groups will be studied, one where the HCP receives the mirror information on GDMT and one where both the patient and the HCP receive the mirror information on GDMT. GDMT or the 4 pillars treatment is standard of care as recommended by the ESC HF guidelines, indicated for all HFrEF patients. The project is a quality of care registry and health care evaluation to optimize adherence to the HF guidelines.",[26,27],"HFrEF - Heart Failure With Reduced Ejection Fraction","Guideline Adherence",[29],"guideline recommended drug therapy","NOT_YET_RECRUITING","2026-07-13",{"date":33,"type":34},"2026-07-14","ACTUAL",{"date":36,"type":21},"2026-07-07",{"date":38,"type":21},"2029-12-01",{"name":40,"class":41},"Jasper Brugts MD PhD","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100473634","guideline-adherence-for-preoperative-anemia-management-in-a-pac-100473634","NCT05447442","Guideline Adherence for Preoperative Anemia Management in a PAC","Adherence to the Hospital Guideline for Evaluation and Management of Preoperative Anemia in Preanesthesia Assessment Center (SIPAC), Siriraj Hospital","Inclusion Criteria Patients who attend a preanesthesia clinic and have anemia.\n\nAnemia defined as\n\n1. Patients, with chronic kidney disease (CKD) stage 3+ or hematologic disease, have a hemoglobin level less than 10 g\u002FdL; or\n2. Patients other than No. 1 and have hemoglobin level less than 13 g\u002FdL in men or a hemoglobin level less than 12 g\u002FdL in women.\n\nExclusion Criteria:\n\n* none",{"count":50,"type":21},93,"Anemia in surgical patients is a common seriously problem; around 40 % of patients presenting for major surgery are anemic problem. Patients with major surgery have significantly higher rates of acute blood loss. Whereas , patients with pre-operative anemia prone to be transfused blood component in pre-operative or intraoperative and postoperative periods that associated with worse outcomes , prolonged hospital stays , increased risk of morbidity and mortality . Therefore, patients undergoing major surgery should be optimization for pre-operative anemia.\n\nIn November 2021, Siriraj Preanesthesia Assessment Center (SIPAC) has developed and implemented a preoperative anemia management guideline which is one pillar of perioperative patient blood management. The objective of this guideline is to optimize red blood cell mass before patients having operation. The investigators are realize the important of pre-operative anemia of patients who undergoing elective surgery. The investigators will aim to evaluate adherence to the preoperative anemia management guideline protocol and perioperative outcomes and use the data of this study to setting guidelines for preoperative anemia evaluation and management in SIPAC of department of anesthesiology in Siriraj hospital for improving workflow and optimization before elective surgery, supporting to a reduction in blood transfusion, hospital stay, morbidity and health care costs of public health of Thailand.",[27,53],"Anemia","RECRUITING","2026-03-04",{"date":57,"type":34},"2026-03-06",{"date":59,"type":34},"2022-10-01",{"date":61,"type":21},"2026-12",{"name":63,"class":41},"Siriraj Hospital",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":74,"studyType":23,"phases":4,"briefSummary":75,"conditions":76,"keywords":82,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100608082","valvular-heart-disease-in-women-registry-100608082","NCT07196930","Valvular Heart Disease in Women Registry","VHD-W","Inclusion Criteria:\n\n* Adult patients with diagnosis of any VHD according to the current ESC guidelines.\n* Admission to the VHD-W Registry collaborating center.\n\nExclusion Criteria:\n\n* Age less than 18 years old.\n* Inability to provide informed consent per local institutional and regulatory requirements.",{"count":73,"type":21},800,"1 Year","Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity\u002Fmortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.",[77,78,27,79,80,81],"Valve Disease, Heart","Gender Bias","Guideline Implementation","Disparities","Registry",[83,84,85,86,87],"valvular heart disease","registry","cardiovascular disease","gender disparities","Guidelines adherence","2025-09-19",{"date":90,"type":34},"2025-09-29",{"date":92,"type":34},"2024-04-01",{"date":94,"type":21},"2030-12",{"name":69,"class":96},"NETWORK",2]